title: IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection.
abstract: Tuberculosis (TB) has huge impact on human morbidity and mortality and biomarkers to support rapid TB diagnosis and ensure treatment initiation and cure are needed, especially in regions with high prevalence of multi-drug resistant TB. Soluble interferon gamma inducible protein 10 (IP-10) analyzed from dry plasma spots (DPS) has potential as an immunodiagnostic marker in TB infection. We analyzed IP-10 levels in plasma directly and extracted from DPS in parallel by ELISA from 34 clinically well characterized patients with TB disease before and throughout 24 weeks of effective anti-TB chemotherapy. We detected a significant decline of IP-10 levels in both plasma and DPS already after two weeks of therapy with good correlation between the tests. This was observed both in pulmonary and extrapulmonary TB. In conclusion, plasma IP-10 may serve as an early biomarker for anti-TB chemotherapy responses and the IP-10 DPS method has potential to be developed into a point-of care test for use in resource-limited settings. Further studies must be performed to validate the use of IP-10 DPS in TB high endemic countries.
authors.affiliation: 1] Institute of Clinical Medicine, University of Oslo, Norway [2] Department of Infectious Diseases, Oslo University Hospital, Norway.
authors.forename: Kristian
authors.initials: K
authors.lastname: Tonby
authors.affiliation: Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
authors.forename: Morten
authors.initials: M
authors.lastname: Ruhwald
authors.affiliation: 1] Institute of Clinical Medicine, University of Oslo, Norway [2] Department of Infectious Diseases, Oslo University Hospital, Norway [3] K. G. Jebsen Center for Inflammation Research, University of Oslo, Norway.
authors.forename: Dag
authors.initials: D
authors.lastname: Kvale
authors.affiliation: 1] Institute of Clinical Medicine, University of Oslo, Norway [2] Department of Infectious Diseases, Oslo University Hospital, Norway [3] K. G. Jebsen Center for Inflammation Research, University of Oslo, Norway.
authors.forename: Anne Ma
authors.initials: AM
authors.lastname: Dyrhol-Riise
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D054357:Chemokine CXCL10 / Q000097:blood*; D015331:Cohort Studies; D059788:Dried Blood Spot Testing; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification / Q000472:pathogenicity; D014376:Tuberculosis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D015415:Biomarkers; C114753:CXCL10 protein, human; D054357:Chemokine CXCL10